Form 4: OrbiMed Advisors Sells TELA Bio Shares in Multiple Transactions

OrbiMed Advisors LLC, a significant shareholder of TELA Bio, Inc., has sold a portion of its holdings in a series of transactions between June 28, 2024, and July 2, 2024.

Summary

• OrbiMed Advisors LLC, along with OrbiMed Capital GP IV LLC, has reported the sale of TELA Bio, Inc. common stock.
• The transactions occurred between June 28, 2024, and July 2, 2024.
• On June 28, 2024, 378,000 shares were sold at a price of $4.74 per share.
• On July 1, 2024, 13,700 shares were sold at $4.68 per share.
• On July 2, 2024, 36,600 shares were sold at $4.54 per share.
• Following these transactions, OrbiMed Advisors indirectly holds 2,407,242 shares of TELA Bio common stock.
• OrbiMed Advisors disclaims beneficial ownership of the securities except to the extent of its pecuniary interest.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative as a major shareholder is reducing their position, which could create selling pressure. However, the document is simply reporting transactions.

Negatives

• OrbiMed Advisors, a significant shareholder, has reduced its stake in TELA Bio, which could be perceived negatively by the market.

Risks

• Continued selling pressure from major shareholders like OrbiMed could negatively impact TELA Bio's stock price.

Management Comments

• Carl L. Gordon of OrbiMed Advisors LLC disclaims beneficial ownership of the securities held by OPI IV except to the extent of its pecuniary interest.

Industry Context

Share sales by major holders are common and can be for various reasons, including portfolio rebalancing or profit-taking. The impact on TELA Bio depends on market perception and the overall health of the company.

Stakeholder Impact

• Shareholders may react to the news of OrbiMed's share sales, potentially impacting the stock price.
• The company's management will need to manage investor relations in light of these transactions.

Key Dates